Sector News

IDEX Corporation appoints Mark A. Beck to Board of Directors

January 3, 2018
Life sciences

IDEX Corporation announced today the appointment of Mark A. Beck to the company’s Board of Directors, effective January 1, 2018.

“We are thrilled to welcome Mark to our Board of Directors,” said IDEX Chairman and Chief Executive Officer Andrew Silvernail. “His experience as a chief executive officer of a public company with significant international operations and his track record of innovation and successfully integrating acquired businesses will be a tremendous asset to IDEX. Mark is a values-based, results-oriented leader, making him a great fit with our Board and management.”

Beck has served as President and Chief Executive Officer of JELD-WEN Holding, Inc. (“JELD-WEN”), one of the world’s largest door and window manufacturers, since November 2015, and was appointed as a Director of JELD-WEN in May 2016. He joined JELD-WEN from Danaher Corporation, where he served as Executive Vice President, leading Danaher’s Water Quality and Dental platforms, beginning in April 2014. Previously, he spent 18 years with Corning Incorporated in a series of management positions with increasing responsibility, culminating in his appointment as Executive Vice President overseeing Corning’s Environmental Technologies and Life Science units in July 2012. He also served on the board of directors of Dow-Corning Corporation from 2010 to 2014. Beck holds a B.A. in Business Management from Pacific University and an M.B.A. from Harvard Business School.

Source: IDEX

comments closed

Related News

May 27, 2023

Positive opinion for Novo Nordisk’s Sogroya

Life sciences

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.

May 27, 2023

Medtronic acquires insulin patch pump maker EOFlow for $738M amid new MiniMed rollout

Life sciences

Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.

May 27, 2023

Apnimed cracks sleep apnea puzzle, hits primary goal in phase 2 study

Life sciences

Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”

How can we help you?

We're easy to reach